Skip to main content
SpringerLink
Log in

Symptoms: Chemotherapy-Induced Peripheral Neuropathy

  • Chapter
Improving Outcomes for Breast Cancer Survivors

Part of the book series: Advances in Experimental Medicine and Biology ((BCRF,volume 862))

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specific factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77

    Article  PubMed  Google Scholar 

  • Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9:807–819

    Article  PubMed  Google Scholar 

  • Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19:833–841

    Article  PubMed Central  PubMed  Google Scholar 

  • Beutler AS, Kulkarni A, Kanwar R, Qin R, Cunningham JM, Therneau TM, Loprinzi CL (2013) Abstract LB-196: sequencing symptom control: results from the alliance N08C1 and N08CA genetics of chemotherapy neuropathy trials. Cancer Res 73(1)

    Google Scholar 

  • Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. Accessed 31 Mar 2003

    Google Scholar 

  • Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38:1832–1837

    Article  CAS  PubMed  Google Scholar 

  • Cavaletti G, Tredici G, Braga M, Tazzari S (1995) Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133:64–72

    Article  CAS  PubMed  Google Scholar 

  • Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, CI-PeriNomS Group (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454–462

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 98:822–831

    Article  CAS  PubMed  Google Scholar 

  • Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, Mcleod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, Kroetz DL (2014) Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J 14(4):336–342

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Flatters SJ, Bennett GJ (2006) Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122:245–257

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ghersi D, Wilcken N, Simes RJ (2005) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93:293–301

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Gogas H, Shapiro F, Aghajanian C, Fennelly D, Almadrones L, Hoskins WJ, Spriggs DR (1996) The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 61:22–26

    Article  CAS  PubMed  Google Scholar 

  • Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM, Stella PJ JR, Johnson JA (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203

    Google Scholar 

  • Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767–774

    Article  CAS  PubMed  Google Scholar 

  • Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 32:1941–1967

    Article  CAS  PubMed  Google Scholar 

  • Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, Mcleod HL, Carey LA, Dees EC (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24:1472–1478

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW (2006) Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett 405:62–67

    Article  CAS  PubMed  Google Scholar 

  • Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387

    Article  CAS  PubMed  Google Scholar 

  • Kautio AL, Haanpaa M, Saarto T, Kalso E (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 35:31–39

    Article  CAS  PubMed  Google Scholar 

  • Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642

    Article  CAS  PubMed  Google Scholar 

  • Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Nakata T, Yorifuji H (1999) Morphological evidence of the inhibitory effect of taxol on the fast axonal transport. Neurosci Res 35:113–122

    Article  CAS  PubMed  Google Scholar 

  • Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D (2004) Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5:372–380

    Article  CAS  PubMed  Google Scholar 

  • Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387

    Article  CAS  PubMed  Google Scholar 

  • Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, Giussani G, Cavaletti G (2005) Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41:1460–1466

    Article  CAS  PubMed  Google Scholar 

  • Peters CM, Jimenez-Andrade JM, Kuskowski MA, Ghilardi JR, Mantyh PW (2007) An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res 1168:46–59

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Raine CS, Roytta M, Dolich M (1987) Microtubule-mitochondrial associations in regenerating axons after taxol intoxication. J Neurocytol 16:461–468

    Article  CAS  PubMed  Google Scholar 

  • Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, North Central Cancer Treatment Group (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118

    Article  CAS  PubMed  Google Scholar 

  • Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Renno SI, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802–2808

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr (15):107–115

    Google Scholar 

  • Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993b) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15

    CAS  PubMed  Google Scholar 

  • Schneider BP, Li L, Miller K, Flockhart D, Radovich M, Hancock BA, Kassem N, Foroud T, Koller DL, Badve SS, Li Z, Partridge AH, O’Neill AM, Sparano JA, Dang CT, Northfelt DW, Smith ML, Railey E, Sledge GW (2011) Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. J Clin Oncol 29(suppl; abstr 1000):80s

    Google Scholar 

  • Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials In Oncology (2013a) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Smith ML, Railey E, White CB, Schneider BP (2013b) Discerning clinical relevance of biomarkers in early stage breast cancer. The San Antonio breast cancer symposium, abstract P6-08-05

    Google Scholar 

  • Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC JR, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671

    Google Scholar 

  • Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JH (2009) NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 7(5):S1–S26, quiz S27–8

    PubMed  Google Scholar 

  • Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Livingston RB, Albain KS, Hayes DF, Ambrosone CB (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130:993–1002

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Theiss C, Meller K (2000) Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res 299:213–224

    Article  CAS  PubMed  Google Scholar 

  • Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85:392–398

    Article  PubMed  Google Scholar 

  • Witte H, Neukirchen D, Bradke F (2008) Microtubule stabilization specifies initial neuronal polarization. J Cell Biol 180:619–632

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine & Medical/Molecular Genetics, Indiana University Simon Cancer Center, Indianapolis, IN, USA

    Bryan P. Schneider (Associate Professor)

  2. Medicine and Epidemiology, Herbert Irving Comprehensive Cancer Center, Columbia University, 161 Fort Washington, 1068, New York, NY, 10032, USA

    Dawn L. Hershman (Associate Professor)

  3. Breast Cancer Research, Division of Medical Oncology, Rochester, MN, USA

    Charles Loprinzi (Regis Professor)

Authors
  1. Bryan P. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dawn L. Hershman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles Loprinzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bryan P. Schneider .

Editor information

Editors and Affiliations

  1. Distinguished Professor of Health Policy & Management and Medicine, Director, Cancer Prevention & Control Research, UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA

    Patricia A. Ganz

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Breast Cancer Research Foundation

About this chapter

Cite this chapter

Schneider, B.P., Hershman, D.L., Loprinzi, C. (2015). Symptoms: Chemotherapy-Induced Peripheral Neuropathy. In: Ganz, P. (eds) Improving Outcomes for Breast Cancer Survivors. Advances in Experimental Medicine and Biology(), vol 862. Springer, Cham. https://doi.org/10.1007/978-3-319-16366-6_6

Download citation

Publish with us

Policies and ethics

Search

Navigation